RBS2418 with Tremelimumab and Durvalumab for Advanced Liver Cancer
This study is evaluating a new treatment called RBS2418 in combination with an existing therapy, STRIDE (tremelimumab plus durvalumab), for people with advanced liver cancer (hepatocellular carcinoma) that cannot be removed by surgery. RBS2418 is designed to boost your body's immune response against cancer. Researchers want to see if adding RBS2418 to STRIDE is safe, well-tolerated, and more effective at stopping cancer growth than STRIDE alone. The main goal is to measure how long participants live without their cancer getting worse (Progression Free Survival). Up to 220 participants will be enrolled. The study is currently recruiting.
- Study design
- This study plans to enroll up to 220 participants. Participants will receive either RBS2418 at two different dose levels combined with STRIDE, or STRIDE alone.
- What's involved
- You would receive study treatment in 28-day cycles for up to two years, or until your disease progresses, you withdraw, or the study ends. You will also need to provide a tissue sample before treatment.
- Compensation
- Not stated in the trial record.
- Follow-up
- Adverse events will be monitored for up to 30 days after your last dose of RBS2418, or until they resolve. Serious adverse events will be collected for 90 days after your last dose.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma
At a glance
Conditions
NCT07175441
Where you'd take part
This study runs at 4 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Johns Hopkins
Baltimore, Marylandno site contact published
Recruiting
START Dallas Fort Worth
Fort Worth, Texasno site contact published
Recruiting
University of Texas Southwestern
Dallas, Texasno site contact published
Recruiting
Vanderbilt-Ingram Cancer Center
Nashville, Tennesseeno site contact published
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Progression Free Survival (PFS)From randomization until the first radiographic documentation of objective progression or death from any cause, assessed up to 2 years.
Time in months from randomization until the first radiographic documentation of objective progression, as assessed using RECIST 1.1, or death from any cause.